
TLSI
USDTriSalus Life Sciences Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$4.380
Kõrge
$4.410
Madal
$4.277
Maht
0.10M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
218.9M
Tööstusharu
Meditsiiniseadmed
Riik
United States
Kauplemisstatistika
Keskmine maht
0.12M
Börs
NGM
Valuuta
USD
52 nädala vahemik
Tehisintellekti analüüsiaruanne
Viimati uuendatud: 26. okt 2025TLSI (TriSalus Life Sciences): Unlocking Value in Oncology Tech
Key Insights at a Glance
- Upside Catalysts: AI models project 1.1%-2.8% gains over 3 days, aligning with recent technical signals near key support.
- Fundamental Edge: P/E ratio (-4.3x) beats industry average (-6.5x), while revenue growth (52%) outpaces peers.
- Risk Factors: Low volatility (beta <1) paired with thin trading volume may limit liquidity; 3/5 risk rating.
- Strategic Play: $5.12 support zone matches entry targets, but stop-loss at $4.60 guards against sudden swings.
Technical Signals: Mixed Momentum, Clear Support
- Bearish DMI: ADX at 11.7 confirms weak trend strength (-DI 14.8 vs. +DI 14.0).
- OBV Surge: Volume spiked 1.6x average on October 23, hinting of accumulation.
- MACD Warning: Death cross (MACD 0.0052 < signal 0.0127) signals short-term weakness.
- Bollinger Band Breakthrough: Price hovers near $5.12 support, a level not breached since October 17.
Trade Setup: Watch for a
Seotud uudised
TriSalus Life Sciences to Participate in Upcoming September Investor Conferences
TriSalus Life Sciences® Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid
Tehisintellekti ennustusBeta
Tehisintellekti soovitus
Uuendatud kell: 10. nov 2025, 10:21
68.0% Kindlus
Risk ja kauplemine
Sisenemispunkt
$4.39
Võta kasum
$4.80
Peata kahjum
$3.96
Põhitegurid
Seotud aktsiad
WSR
Whitestone REIT Common Shares
NTAP
NetApp Inc.
CNDT
Conduent Incorporated
ONBPO
Old National Bancorp Depositary Shares Each Representing a 1/40th Interest in a Share of Series C Preferred Stock
CC
Chemours Company (The)
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.